CORAL Study Brings Positive News for Adults With Depression

Coadministration of zuranolone with a standard antidepressant yields positive outcomes.

Sagar Parikh, MD, FRCPC, shares news about the CORAL Study examining zuranolone treatment in patients with major depressive disorder, which demonstrated a rapid and statistically significant reduction in depressive symptoms at day 3 and over the 2-week treatment period.

To read more about this study, see: Improving Depression Symptoms: Study Meets Endpoints.

Dr Parikh is a professor of Depression and Clinical Neuroscience, and Psychiatry Sciences, at the University of Michigan.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2023 MJH Life Sciences

All rights reserved.